Morgan Stanley reiterates BioMarin stock rating on settlement value

The market is likely underappreciating how much of the re-rating is coming from de-risking, not from the royalty stream itself. For BMRN, the immediate benefit is a cleaner legal overhang and a more visible IP monetization story, which can support a higher multiple even if the cash contribution is modest; for Ascendis, the cost is not just the royalty burden but the precedent that future commercialization can be taxed through settlement rather than won outright. That dynamic usually matters more to biotech valuations than the headline royalty rate: it lowers the probability of a near-term injunction, but it also caps the long-run economics of the franchise.

Second-order, this is constructive for large-cap rare disease names with defensible IP and balance sheets, while smaller biotech names with unresolved patent exposure may face higher discount rates as litigants demand economics instead of risking ITC outcomes. The broader sector implication is that binary litigation risk may compress less than investors expect because settlements preserve operating continuity; that is positive for sell-side models but not necessarily for ultimate upside if the market was hoping for exclusionary relief. The acquisition element adds a separate risk: if capital is diverted into small M&A with no operating employees transferred, the rerating can stall once the legal catalyst fades.

The key test over the next 1-3 months is whether management quantifies incremental royalty value and whether consensus lifts 2025-26 FCF or just EPS optics. Over 6-18 months, the thesis is only durable if BMRN can show that legal wins translate into durable margin expansion and not just one-time cash receipts. What would falsify it: no visible upward revision to revenue/FCF guidance, another patent challenge, or the stock failing to hold the low-$60s despite the settlement being fully digested.